Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder

Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addicti...

Full description

Bibliographic Details
Main Authors: Ming-Fen Ho, Cheng Zhang, Irene Moon, Brandon J. Coombes, Joanna Biernacka, Michelle Skime, Doo-Sup Choi, Paul E. Croarkin, Mark A. Frye, Quyen Ngo, Cedric Skillon, Tyler S. Oesterle, Victor M. Karpyak, Hu Li, Richard M. Weinshilboum
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
alcohol use disorder
acamprosate
TNFSF10
proteomics
alcohol craving
treatment outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.986238/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.986238/full

Similar Items